Effect of temporary suspension of chronic immunosuppressive drugs on day-90 mortality and ICU-acquired infections among critically Ill patients with solid organ transplant: a retrospective multicenter study

dc.contributor.author Szychowiak, Piotr
dc.contributor.author Lacherade, Jean-Claude
dc.contributor.author Vaidie, Julien
dc.contributor.author François, Bruno
dc.contributor.author Pene, Frédéric
dc.contributor.author Vignon, Philippe
dc.contributor.author Evrard, Bruno
dc.contributor.author Zalucky, Ann
dc.contributor.author Gabriel, Anthony
dc.contributor.author Péju, Edwige
dc.contributor.author Guillon, Antoine
dc.contributor.author Demiselle, Julien
dc.contributor.author Asfar, Pierre
dc.contributor.author Guillot, Pauline
dc.contributor.author Delange, Boris
dc.date.accessioned 2025-12-31T12:52:29Z
dc.date.available 2025-12-31T12:52:29Z
dc.date.issued 2025-07-16
dc.description Purpose: Decision-making for management of immunosuppressive drugs in solid organ transplant patients admitted to the ICU remains controversial. This study aimed to evaluate the impact of a temporary suspension strategy (interruption of immunosuppressive drugs > 24h) on day-90 mortality and ICU-acquired infections.Methods: This multicenter observational retrospective study conducted in solid organ transplant patients admitted to nine ICUs used a Bayesian approach with priors based on a belief elicitation process conducted among a panel of experts.Results: Among 591 enrolled patients, suspension strategy was used in 34% of them, during a median period of 5 days [IQR: 3-10]. This approach was more common in patients admitted for sepsis (38%) or COVID-19 (49%) than for non-septic causes (24%) (p < 0.001). Overall, day-90 mortality reached 30%, and Bayesian analysis revealed substantial uncertainty with an OR at 1.13 (95% Credible Interval (CrI): 0.74-1.70), and a 15% probability of a beneficial effect. In the subgroup of patients with sepsis, OR was at 0.90 (95% CrI: 0.55-1.55), with a 50% probability of a beneficial effect. ICU-acquired infections occurred in 26% of patients. The suspension strategy indicated a potential benefit, both in the entire cohort, with a 73% probability of a beneficial effect [OR: 0.74 (95% CrI: 0.49-1.15)], and in the subgroup of sepsis patients with a 78% probability of beneficial effect [OR 0.70 (95% CrI, 0.42-1.16)].Conclusion: Temporary suspension of immunosuppressive drugs may reduce the risk of ICU-acquired infections, with a true uncertainty on day-90 mortality. Prospective studies are warranted to confirm these results.
dc.description.epage 1452
dc.description.spage 1442
dc.description.volume 51
dc.identifier.doi 10.1007/s00134-025-08024-7
dc.identifier.issn 1432-1238
dc.identifier.uri https://ror.circle-u.eu/handle/123456789/1690815
dc.openaire.affiliation Université Paris Cité
dc.openaire.collaboration 1
dc.publisher Springer Science and Business Media LLC
dc.rights CLOSED
dc.rights.license c_14cb
dc.source Intensive Care Medicine
dc.subject Immunosuppression
dc.subject Internal medicine
dc.subject Cohort study
dc.subject Immunosuppressive agents
dc.subject Treatment outcome
dc.subject Intensive care medicine
dc.subject Emergency medicine
dc.subject Medicine
dc.subject Nosocomial infections
dc.subject Observational study
dc.subject Sepsis
dc.subject Critical care
dc.subject Organ transplantation
dc.subject [SDV.IB] Life Sciences [q-bio]/Bioengineering
dc.subject Retrospective cohort study
dc.title Effect of temporary suspension of chronic immunosuppressive drugs on day-90 mortality and ICU-acquired infections among critically Ill patients with solid organ transplant: a retrospective multicenter study
dc.type publication

Files

Collections